Clinical Trial Update: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 trial investigating human plasma-derived alpha1-proteinase inhibitor in newly diagnosed Type 1 Diabetes mellitus was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Alpha1-Proteinase Inhibitor (human plasma-derived) (alpha1-proteinase inhibitor)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: TERMINATED | Results posted: 2018-04-19